AN UNUSUAL TYPE 2A VON WILLEBRAND DISEASE PHENOTYPE WITH ASSOCIATED THROMBOCYTOPAENIA.
THE OUTCOMES OF AMBULATORY DVT MANAGEMENT USING MULTIDISCIPLINARY APPROACH
THE AMOUNT OF ABH ANTIGEN ON PLASMA VWF IS DETERMINED BY ABO GENOTYPE AND IS A MAJOR DETERMINANT OF PLASMA VWF:AG LEVELS.
HAEMOSTATIC VARIABLES, INCIDENT CORONARY HEART DISEASE AND EFFECTS OF PRAVASTATIN: THE WEST OF SCOTLAND CORONARY PREVENTION STUDY
THE ROLE OF VWF-CLEAVING PROTEASE ACTIVITY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA
PROTHROMBOTIC GENOTYPES AND PREDISPOSITION TO PRE-ECLAMPSIA AND GESTATIONAL HYPERTENSION: NO EVIDENCE OF A SIGNIFICANT EFFECT IN A LARGE POPULATION-BASED STUDY
GENETIC ANALYSIS OF FIBRINOGEN AND CRP PLASMA LEVELS
REDUCED TISSUE FACTOR PATHWAY INHIBITOR ACTIVITY IN PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME.
IN VIVO CAMPATH RESULTS IN RAPID DEPLETION OF HOST DENDRITIC CELLS (DC) PRIOR TO ALLOGENEIC TRANSPLANTATION BUT DOES NOT DELAY DONOR DC RECONSTITUTION POST-TRANSPLANT
NARROWING AND GENOMIC ANNOTATION OF THE CRITICAL REGION OF THE 5q- SYNDROME
INDUCTION OF MOLECULAR RESPONSES IN CLL USING HIGH-DOSE TREATMENT COMBINED WITH AUTOLOGOUS RESCUE.
MATCHING FOR HLA DPB1 INCREASES THE SURVIVAL IN UNRELATED STEM CELL TRANSPLANTS, HOWEVER IS ASSOCIATED WITH AN INCREASED RELAPSE RATE.
PRIMITIVE, QUIESCENT, HAEMOPOIETIC STEM CELLS RESISTANT TO STI571 AND REVEALED BY HIGH RESOLUTION TRACKING OF CELL DIVISION EXIST IN ALL CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS.
THE IMPLICATIONS & CHARACTERISATION OF A SOLUBLE PROTEIN SECRETED BY PRIMARY AML CELLS THAT INHIBITS T CELL ACTIVATION.
CD8+ T CELLS REACTIVE TO BCR-ABL JUNCTIONAL PEPTIDES CIRCULATE IN CML PATIENTS AND MAY BE EXPANDED IN VITRO.
HLA-ASSOCIATED PEPTIDES DERIVED FROM BCR-ABL ARE EXPRESSED ON THE CML CELL SURFACE.
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN MDS: INTERIM RESULTS OF OUTCOME FOLLOWING NON-MYELOABLATIVE CONDITIONING COMPARED TO STANDARD PREPARATIVE REGIMENS.
A SENSITIVE CYTOKINE SECRETION ASSAY TO QUANTITATE AND ISOLATE VIABALE ALLOSPECIFIC T CELLS.
UPDATED RESULTS OF NON-MYELOABLATIVE ALLOGRAFTING WITH BEAM-CAMPATH CONDITIONING IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASE.
TARGETING PML/RARα TRANSCRIPT BY DNAZYME RESULTS IN REDUCTION OF PROLIFERATION IN APL CELLS.
GENERATION OF DENDRITIC CELLS FROM PBPC HARVESTS FROM PATIENTS WITH AML AND MYELOMA AND NORMAL DONORS.
GLYCOGEN SYNTHASE KINASE-3 REGULATES APOPTOSIS IN PRIMARY HUMAN ERYTHROBLASTS
CONSTRUCTION OF A CHROMOSOME 11Q22-23 BAC/PAC CONTIG AND APPLICATION OF GENOMIC REAL-TIME PCR TO CHARACTERISE CHROMOSOME DELETIONS IN LYMPHOID TUMOURS
NONINVASIVE DETERMINATION OF HEMOGLOBIN BY DIGITAL PHOTOGRAPHY OF PALPEBRAL CONJUNCTIVA
Inhibitor of apoptosis c-IAP1 suppresses TNFα-induced apoptosis upstream of mitochondria in human leukaemic U937 cells.
Apaf-1XL is an inactive isoform compared with Apaf-1L in human leukaemic cells
CONGENITAL VENOUS ANOMALIES AS A RISK FACTOR FOR DEEP VENOUS THROMBOSIS
INVERSE RELATIONSHIP BETWEEN PLASMA VON WILLEBRAND FACTOR AND SOLUBLE P SELECTIN IN PATIENTS WITH TYPE 1 BUT NOT TYPE 2 VON WILLEBRAND DISEASE.
INCREASED LEVELS OF PLASMA GLYCOPROTEIN V IN PERIPHERAL AND CORONARY ARTERY DISEASE
RECOMBINANT CRP INDUCES INCREASED SECRETION OF ICAM AND THROMBOMODULIN, BUT NOT VWF OR E SELECTIN, FROM HUVECs
SUCCESSFUL MANAGEMENT OF A PATIENT WITH ACQUIRED VON WILLEBRAND DISEASE REQUIRING MAJOR PELVIC SURGERY USING A COMBINATION OF HIGH DOSE IMMUNOGLOBULING INFUSIONS AND PLASMAPHERESIS.
ASSESSMENT OF THE EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON BONE MINERAL DENSITY IN PREGNANCY BY SERIAL DUAL ENERGY X-RAY ABSORPTIOMETRY(DXA) SCANNING
ACQUIRED DEFICIENCIES OF PROTEIN C AND ANTITHROMBIN III ARE RAPIDLY IDENTIFIABLE THROUGH WAVEFORM ANALYSIS
MARKED ELEVATION OF THROMBIN GENERATION IN PATIENTS WITH ELEVATED PLASMA FVIII:C LEVELS AND VENOUS THROMBOEMBOLISM.
CONCORDANT FVIII:VWF RATIO ACROSS ABO BLOOD GROUP GENOTYPES SUGGESTS THE EFFECT OF THE ABO LOCUS ON PLASMA FVIII/VWF LEVELS IS MEDIATED BY RATE OF CLEARANCE.
SECRETOR BLOOD GROUP GENOTYPE DOES NOT INFLUENCE PLASMA CONCENTRATION OF FACTOR VIII OR VON WILLEBRAND FACTOR.
RISK ASSESSMENT OF NURSE LED AMBULATORY DVT MANAGEMENT VERSUS STANDARD MEDICAL ADMISSION IN RESPECT OF DIAGNOSIS AND SUBSEQUENT DEVELOPMENT OF MALIGNANCY.
HUMAN MONOCLONAL ANTIBODIES AGAINST PLATELET AUTO-ANTIGENS.
A DISTRICT GENERAL HOSPITAL'S EXPERIENCE WITH ENOXAPARIN IN PREGNANCY.
THE EFFECT ON THE PATIENT CARE PATHWAY OF INTRODUCING A D-DIMER SCREENING TEST FOR SUSPECTED ACUTE DVT
AN AUDIT OF LABORATORY INVESTIGATION OF ANTIPHOSPHOLIPID SYNDROME
PREVALENCE OF ANTIBODIES TO BETA 2 GLYCOPROTEIN I AND PROTHROMBIN IN A CLINIC POPULATION OF ISCHAEMIC STROKE
THE BETA2-GLYCOPROTEIN I TRP316SER POLYMORPHISM DOES NOT PROTECT AGAINST THE DEVELOPMENT OF PRIMARY ANTIPHOSPHOLIPID SYNDROME
NEAR PATIENT TESTING (POINT OF CARE) EXERCISES IN UK NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME FOR BLOOD COAGULATION: LONG TERM EXPERIENCES.
AUTOMATED D-DIMER MEASUREMENT, USING THE MDA 180, IN THE INITIAL ASSESSMENT OF DEEP VEIN THROMBOSIS
EVALUATION OF KITS FOR THE ASSESSMENT OF THE PROTEIN C PATHWAY
POINT OF CARE MONITORING OF ORAL ANTICOAGULATION USING THE COAGUCHEK S.
INCREASED CLOTTABLE, TOTAL AND HYPERFUNCTIONAL FIBRINOGEN LEVELS IN PREVIOUS MYOCARDIAL INFARCTION ARE NOT EXPLAINED BY MARKERS OF ACUTE PHASE REACTIONS.
ASSOCIATIONS OF HAEMOSTATIC FACTORS WITH BODY MASS INDEX.
PROCOAGULANT RESPONSES TO AIRBORNE POLLUTANTS
FACTOR V HR2 HAPLOTYPE IN VENOUS THROMBOSIS AND THE NORMAL POPULATION IN THE UK
PLATELET CD36 AND ARACHIDONIC ACID AVAILABILITY IN HEALTH, MYELOPROLIFERATIVE DISEASE AND TYPE 2 DIABETES MELLITUS
INVOLVEMENT OF THE INTRINSIC PATHWAY OF BLOOD COAGULATION IN THROMBUS FORMATION AT THE SITE OF ATHEROSCLEROTIC LESION.
FACTOR VIII ANALYSIS AND THROMBOELASTOGRAPHY IN PATIENTS WITH RETINAL VEIN THROMBOSIS.
COMPARISON OF COAGUCHEK-S AND COAGUCHEK FOR DETERMINATION OF INR
RAPID REVERSAL OF ORAL ANTICOAGULATION WITH WARFARIN BY A PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX): EFFICACY AND SAFETY IN 36 PATIENTS.
LOCAL CALIBRATION OF INR SYSTEMS: RESULTS WITH DIFFERENT CALIBRANTS.
CLINICAL SYMPTOMS AND SIGNS DO NOT PREDICT THE PRESENCE OF MIXED CRYOGLOBULINAEMIA IN PATIENTS WHO HAVE ACQUIRED HEPATITIS C INFECTION FOLLOWING POOLED BLOOD PRODUCT EXPOSURE.
TISSUE FACTOR EXPRESSION ON MONOCYTE SUBSETS DURING PREGNANCY.
DIRECT SEQUENCING OF FACTOR VIII MUTATIONS IN HAEMOPHILIA A PATIENTS.
ENDOGENOUS FIBRINOLYTIC ACTIVITY AND RESPONSE TO THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
ATHEROSCLEROSIS AND CIGARETTE SMOKING:DIRECT LINK BETWEEN ENDOTHELIAL DYSFUNCTION AND ATHEROTHROMBOSIS.
THE EFFECT OF ORTHOPAEDIC SURGERY FOR HAEMOPHILIC ARTHROPATHY ON FACTOR VIII REQUIREMENT.
ANTITHROMBIN REPLACEMENT IN SEVERE SEPSIS: EFFECT ON HAEMOSTATIC MARKERS AND CLINICAL OUTCOME.
DIFFERENCES IN CLEARANCE OF PLASMA-DERIVED VERSUS RECOMBINANT FACTOR VIII AND IX DURING CONTINUOUS INFUSION
EVALUATION OF AN AUTOMATED LATEX PARTICLE METHOD FOR THE MEASUREMENT OF VWF ANTIGEN IN PATIENTS RECEIVING TREATMENT.
PREVALENCE OF THE TNFB POLYMORPHISM IN INFLAMMATORY BOWEL DISEASE, MENINGOCOCCAL SEPSIS: CASE CONTROL STUDIES.
ACTIVATED PROTEIN C INHIBITS UPREGULATION OF BOTH TISSUE FACTOR AND TNFα IN ENDOTOXIN STIMULATED MONOCYTES.
G TO C TRANSITION IN THE PROMOTER REGION OF THE IL6 GENE IS ASSOCIATED WITH DISEASE OUTCOME IN MENINGOCOCCAL SEPSIS/PURPURA FULMINANS.
EFFICACY AND SAFETY OF DDAVP IN CHILDREN WITH INHERITED BLEEDING DISORDERS
POLYMORPHISMS IN THE GENES ENCODING FIBRINOGEN, ANGIOTENSIN CONVERTING ENZYME AND TISSUE PLASMINOGEN ACTIVATOR ARE ASSOCIATED WITH IBD: A CASE CONTROL STUDY.
VON WILLEBRAND'S DISEASE (VWD): AN IMPORTANT CAUSE OF DYSFUNCTIONAL UTERINE BLEEDING
EVALUATION OF P450 CYP2C9 GENOTYPING IN PATIENTS ON WARFARIN THERAPY
RECOMBINANT FACTOR VIIA (rVIIA) IN THE MANAGEMENT OF SURGERY AND ACUTE BLEEDING EPISODES IN CHILDREN WITH HIGH RESPONDING FACTOR VIII AND FACTOR IX INHIBITORS.
A RAPID ABI 7700 BASED DETECTION SYSTEM FOR THE FACTOR V LEIDEN MUTATION: THE INVADER™ ASSAY.
INCREASED SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) CORRELATE WITH SPLENOMEGALY IN POLYCYTHEMIA
RESISTANCE TO CYTOKINE INDUCED DENDRITIC CELL DIFFERENTIATION IN PRIMARY AML BLASTS CAN BE OVERCOME BY THE ADDITION OF BRYOSTATIN
AJOENE, A GARLIC-DERIVED COMPOUND, ENHANCES CHEMOTHERAPY-INDUCED APOPTOSIS IN HUMAN LEUKAEMIA CD34+ RESISTANT CELLS
THE EFFECT OF THE MEK INHIBITOR U0126 ON AML CELL LINES.
Liposomal DaunoXome diminishes daunorubicin-induced free radical generation and necrosis in human leukaemic cells
Bax translocation is crucial for the sensitivity of leukemic cells to etoposide-induced apoptosis
PAMIDRONATE AND ZOLEDRONIC ACID INDUCE APOPTOSIS IN HUMAN MYELOMA CELLS BY INHIBITING PROTEIN PRENYLATION.
TOTAL TYROSINE PHOSPHORYLATION OF CYCLIN DEPENDENT KINASE 1 (CDK1) PRECEDES DRUG-INDUCED APOPTOSIS IN MYELOID LEUKAEMIC CELLS.
ALPHA-1-ACID GLYCOPROTEIN (AGP) DOES NOT MEDIATE SIGNIFICANT IN VITRO RESISTANCE TO STI571 IN CML
THE CYTOGENETIC RESPONSE TO STI571 AT 3 MONTHS IN PATIENTS WITH MYELOBLASTIC CRISIS OF CML MAY PREDICT SURVIVAL.
mRNA EXPRESSION PATTERN OF D TYPE CYCLINS IN CML PATIENTS.
MURINE MONOCYTIC CELLS EXPRESSING COMMON AML1 TRANSLOCATION PRODUCTS EXPRESS HIGH LEVELS OF GST AND EGR1.
CHROMATIN IMMUNOPRECIPITATION (ChIP) ANALYSIS OF CELLS EXPRESSING THE AML1-ETO GENE.
THE HISTONE DEACETYLASE (HDAC) INHIBITOR TRICHOSTATIN-A (TSA) IS MORE EFFECTIVE THAN TRIBUTYRATE (TB) IN INHIBITING GROWTH AND INDUCING DIFFERENTIATION IN 32D CELLS EXPRESSING VARIANTS OF THE AML GENE.
HISTONE DEACTYLASE INHIBITORS REDUCE GROWTH RATES AND INDUCE DIFFERENTIATION IN NB4 (t(15;17)) ATRA SENSITIVE AND RESISTANT CELLS AND KASUMI (t(8;21)) CELLS.
ACUTE MYELOID LEUKAEMIA OF FAB TYPES M6 AND M4 WITH PML RARα FUSION GENES AT PRESENTATION, RELAPSING AS ACUTE PROMYELOCYTIC LEUKAEMIA M3.
CLINICAL MANAGEMENT OF ACUTE MYELOID LEUKAEMIA IN ELDERLY PATIENTS AT A SINGLE CENTRE (1969-1999)
p53 OVERRIDES THE ETOPOSIDE-INDUCED G2/M BLOCK IN K562 CELLS, LEADING TO ENHANCED APOPTOSIS.
THE CHROMOSOMAL COMPLEXITY SCORE (CCS) AS A PREDICTIVE FACTOR FOR RESPONSE OF PATIENTS WITH CML IN ACCELERATED PHASE TO TREATMENT WITH STI571.
EXPRESSION OF TUMOUR-ASSOCIATED ANTIGENS IN PRESENTATION MYELOID LEUKAEMIAS.
A PHASE II STUDY OF FLUDARABINE, ARA-C, G-CSF + LIPOSOMAL DAUNORUBICIN (FLAG-X) IN HIGH RISK ACUTE LEUKAEMIA AND MDS.
ACUTE MYELOID LEUKAEMIA CELLS SECRETE SOLUBLE FACTORS THAT INHIBIT T AND NK CELL PROLIFERATION BUT NOT CYTOLYTIC FUNCTION - IMPLICATIONS FOR THE ADOPTIVE IMMUNOTHERAPY OF LEUKAEMIA.
AUTOLOGOUS LEUKAEMIA-REACTIVE CD8+ NK CELLS ARE REQUIRED FOR LONG-TERM SURVIVAL AFTER TREATMENT FOR ACUTE LEUKAEMIA.
DIFFERENTIAL EXPRESSION OF HOMEOBOX GENES IN THE LEUKAEMIC CELL LINE HL-60 USING REAL TIME QUANTITATIVE PCR.
APOPTOSIS CAN BE INDUCED IN LEUKAEMIC CELLS BY PROTEASOME INHIBITION.
THE ASSESSMENT OF BCL-2 AND BAX IN ACUTE MYELOID LEUKAEMIA: A COMPARISON OF IMMUNOCYTOCHEMISTRY AND REAL-TIME PCR.
SMALL ARRAY REAL TIME (SMART) QUANTITATIVE PCR PROFILING OF HOX GENES IN AML AND ALL PATIENTS.
HIGH PROGNOSTIC VALUE OF INTERNAL TANDEM DUPLICATIONS OF THE FLT3 GENE IN AML.
SURVIVIN-TARGETING DNAZYMES SUPRESS PROLIFERATION AND INDUCE APOPTOSIS IN MYELOID LEUKAEMIC CELLS.
PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF QUANTITATIVE ANALYSIS OF WT1 GENE TRANSCRIPTS BY COMPETITIVE RT-PCR IN ACUTE LEUKAEMIA.
SUPRESSION OF PROLIFERATION AND INDUCTION OF APOPTOSIS IN MYELOID LEUKAEMIC CELLS BY DNAZYMES TARGETING THE XIAP GENE.
FREQUENT MICROSATELLITE INSTABILITY BUT LACK OF HYPERMETHYLATION OF DNA-MISMATCH REPAIR GENES IN THERAPY-RELATED AND SECONDARY AML AND MDS.
COMPARISON OF SINGLE AND DUAL PLATFORM MEASUREMENT OF CD34+ CELLS, IMPLICATIONS FOR CELL DOSE REQUIREMENT.
UNRELATED DONOR TRANSPLANTATION FOR ADULT AML: FAVOURABLE OUTCOME FOR PATIENTS IN CR1 AND WITH GOOD RISK CYTOGENETICS IN CR2
AUTOLOGOUS TRANSPLANTATION IN POOR RISK HODGKIN'S DISEASE; LONG TERM FOLLOW-UP OF 98 PATIENTS: A REGIONAL EXPERIENCE
BONE MARROW HARVEST AS AN OUTPATIENT: A UK CENTRE EXPERIENCE
CONFOCAL LASER SCANNING MICROSCOPE 3-D REPRESENTATION SUPPORTS CO-LOCALISATION OF SIALOMUCIN MOLECULES CD164/CD34 ON BONE MARROW AND UMBILICAL CORD BLOOD PRIMARY CELLS DURING ADHESION.
GRANULOCYTE-COLONY STIMULATING FACTOR INDUCED STEM CELL MOBILISATION IN NORMAL HUMAN DONORS IS ASSOCIATED WITH ACCUMULATION OF MATRIX METALLO-PROTEINASE 9 IN PLASMA.
CD34-POSITIVE CELL MEMBRANE ANALYSIS BY ELECTRON MICROSCOPY.
CAMPATH 1-H 'IN THE BAG' FOR T CELL DEPLETION IN ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FROM MATCHED FAMILY DONORS REDUCES BOTH ACUTE AND CHRONIC GVHD AND LIMITS TRANSPLANT-RELATED MORTALITY.
THE FEASIBILITY OF NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION (NSCT) USING CHEMOTHERAPY ALONE WITHOUT CAMPATH.
MONITORING CYTOMEGALOVIRUS ANTIGEN SPECIFIC T CELLS IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION.
ESTABLISHMENT AND OPTIMISATION OF A NOVEL NON-MYELOABLATIVE MURINE MIXED CHIMERISM MODEL ACROSS MAJOR MHC-MISMATCHED BARRIERS
HIGH-DOSE MELPHALAN AND AUTOTRANSPLANTATION IN MYELOMA PATIENTS WITH SEVERE RENAL DYSFUNCTION (CREATININE CLEARANCE <20 ML/MIN/M2): HIGH INCIDENCE OF ATRIAL FIBRILLATION AND TREATMENT-RELATED MORTALITY.
PROGRESSIVE REDUCTION IN TREATMENT-RELATED DEATHS IN MRC CHILDHOOD LYMPHOBLASTIC LEUKAEMIA TRIALS FROM 1980-1997 (UKALL VIII, X & XI)
Results of treatment for children with refractory anaemia with excess blasts (RAEB) and in transformation(RAEBt) in Britain 1990-1999
ANALYSIS OF VARIATION IN THE RECOMBINATION ACTIVATING GENE RAG-1 IN CHILDHOOD ACUTE LEUKAEMIA.
BONE MARROW TRANSPLANTATION FOR β THALASSAEMIA MAJOR - EXPERIENCE OF TWO UK CENTRES
MLL CLEAVAGE IN CHILDREN RECEIVING TOPOISOMERASE 2 INHIBITOR THERAPY: A SUITABLE BIOMARKER FOR TREATMENT RELATED LEUKAEMOGENESIS?
TOWARDS GENE THERAPY OF HURLER'S SYNDROME: CORRECTION BY RETROVIRAL GENE TRANSFER OF HURLER'S MESENCHYMAL STEM CELLS.
CARBONIC ANHYDRASE II DEFICIENCY: PHENOTYPE, GENOTYPE AND MARROW TRANSPLANTATION
ALTHOUGH EXTRACORPOREAL PHOTOPHERESIS (ECP) INDUCES EARLY PHOSPHATIDYLSERINE EXPOSURE, CASPASE ACTIVATION IS NOT OBSERVED UNTIL 24 HOURS POST ECP
THE ROLE OF FLUDARABINE AND EPSTEIN BARR VIRUS IN THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL).
MASSIVE TROPICAL SPLENOMEGALY REVISITED
MORPHOLOGY - A HELP OR A HINDRANCE TO THE CLASSIFICATION OF CLL.
Idarubicin-mediated killing in human leukaemia is via a mechanism combining DNA damage, apoptosis and necrosis
PRIMARY CUTANEOUS B-CELL LYMPHOMAS: A CLINICAL FOLLOW-UP STUDY OF 50 PATIENTS
CAMPATH-1H IN CLL: IMMUNE RECONSTITUTION AND VIRAL INFECTIONS DURING AND AFTER THERAPY.
ETOPOSIDE, METHYLPREDNISOLONE, CYTARABINE AND CISPLATIN (ESHAP) AS SECOND-LINE/SALVAGE THERAPY FOR NEWLY DIAGNOSED MYELOMA.
CCR5-Δ32 AND SDF1-3′A VARIANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.
CHARACTERISATION OF HELPER T CELL EPITOPES ON EPSTEIN-BARR VIRUS SURFACE ANTIGENS EXPRESSED IN HODGKIN'S DISEASE
THALIDOMIDE IN RELAPSED/REFRACTORY MYELOMA (MM). MINIMUM DOSAGE SCHEDULE WITH DURABLE RESPONSE.
VEGF-C IS EXPRESSED BY THE MALIGNANT B CELLS OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL).
LEUKAEMIC HAIRY CELLS EXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND BECOME MORE MOTILE UPON VEGF STIMULATION.
ANALYSIS OF THE REACTIVITY OF 20 DENDRITIC CELL ASSOCIATED ANTIBODIES WITH PRECURSOR DENDRITIC CELLS (pDCs) IN THE BLOOD FROM NORMAL SUBJECTS AND PATIENTS WITH CHRONIC LYMPHOID LEUKAEMIA (CLL)
HIGH DOSE CHLORAMBUCIL FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND LOW GRADE NON-HODGKIN'S LYMPHOMA (LG-NHL)
IFOSPHAMIDE, ETOPOSIDE & EPIRUBICIN (IVE) - AN EFFECTIVE SALVAGE & MOBILISATION REGIMEN IN LYMPHOMA.
THALIDOMIDE TREATMENT IN RELAPSED MYELOMA: THE NORTH TRENT EXPERIENCE.
COMPARISON OF HOME VERSUS HOSPITAL ADMINISTRATION OF PAMIDRONATE IN PATIENTS WITH MULTIPLE MYELOMA
PREDICTION OF VH GENE MUTATION STATUS IN B-CLL USING IMMUNOPHENOTYPING AND TREPHINE HISTOLOGY.
THROMBOEMBOLISM(TE) IN PATIENTS ON THALIDOMIDE FOR MYELOMA.
TARGETED RADIOTHERAPY FOR MYELOMA: PRE-CLINICAL AND CLINICAL EVALUATION OF AN ANTI-CD138 Mab.
CONSOLIDATION HIGH DOSE VS INTERMEDIATE DOSE MELPHALAN FOR MYELOMA PRELIMINARY REPORT OF A MULTICENTRE RANDOMISED TRIAL
TOTAL REGISTRATION AND OUTCOME OF NON-HODGKIN'S LYMPHOMA AND HODGKIN'S DISEASE IN SCOTLAND 1994-1996
RESPONSE TO THALIDOMIDE CAN BE PREDICTED BY PARAPROTEIN QUANTITATION 14 DAYS AFTER INITIATING THERAPY.
REPAIR OF DNA INTERSTRAND CROSSLINKS AS A MECHANISM OF CLINICAL RESISTANCE TO MELPHALAN IN MULTIPLE MYELOMA
POOR PROGNOSIS ETV6/AML1 FUSION. FISH REVEALS SOME COMMON FEATURES
EARLY RESPONSE TO INFUSIONAL CHEMOTHERAPY IS AN INDEPENDENT PROGNOSTIC FACTOR IN NEWLY-DIAGNOSED IgG AND IgA MULTIPLE MYELOMA
DURABLE REMISSION AFTER MABTHERA (RITUXIMAB) TREATMENT FOR REFRACTORY IDIOPATHIC COLD HAEMAGGLUTININ DISEASE (CHAD).
A 6 MONTH PROSPECTIVE SURVEY OF LYMPHOCYTOSIS IN 10 LARGE HOSPITALS - INCIDENCE, INVESTIGATION AND MANAGEMENT.
LONG TERM EVALUATION OF FAILURE OF TREATMENT FOR HODGKIN'S DISEASE. SINGLE CENTRE STUDY
THE GEOGRAPHICAL DISTRIBUTION OF CHILDHOOD LEUKAEMIA AND LYMPHOMA IN NORTH WEST ENGLAND.
PLACENTAL VASCULAR COMPLICATIONS AND THE G-455A BETA-FIBRINOGEN GENE POLYMORPHISM
USE OF GEMTUZUMAB OZOGAMICIN ('MYLOTARG') IN A GIRL WITH REFRACTORY RELAPSED ACUTE MYELOID LEUKAEMIA.
FATAL HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) ASSOCIATED WITH MEASLES INFECTION AND PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY
SEARCHING FOR AUTOSOMAL DYSKERATOSIS CONGENITA LOCI; USE OF A SNP TO EXCLUDE NOP10P IN SOME CONSANGUINOUS FAMILIES
THE EFFECT OF BONE MARROW TRANSPLANTATION ON GROWTH IN CHILDREN WITH THALASSAEMIA.
MOLECULAR ANALYSIS OF GENETIC DAMAGE IN LEUKOCYTES FROM PRE-TERM BABIES EXPOSED TO DIAGNOSTIC X-RAYS.
NEONATAL ALLOIMMUNE THROMBOCYTOPENIA COMPLICATED BY CLINICALLY SIGNIFICANT HLA ANTIBODIES.
REFRACTORY AUTOIMMUNE HAEMOLYTIC ANAEMIA IN CHILDHOOD: IS THERE A ROLE FOR RITUXIMAB?
INCREASED ANGIOGENESIS IN BONE MARROW TREPHINE BIOPSY SAMPLES OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA MAY BE A POOR PROGNOSTIC INDICATOR.
CD45 NEGATIVE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN.
OUTCOME FOR CHILDREN FOLLOWING FAILED TRANSPLANT FOR HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.
Bcl-2 EXPRESSION, PROGNOSIS AND TREATMENT RESPONSE IN MYELOMA PATIENTS.
CML LEUKAPHERESIS PRODUCTS CAN BE ENRICHED FOR CD34+ CELLS AND SIMULTANEOUSLY DEPLETED OF CD15+ CELLS USING A SIMPLE ANTIBODY COCKTAIL.
HAEMOCHROMATOSIS: IRON KINETICS & ERYTHROPOIESIS.
ERYTHROPOIESIS IN PREGNANCY - A COHORT STUDY.
COMPENSATED HAEMOLYSIS: A CONSISTENT FEATURE OF DIABETES MELLITUS.
AN IMPROVED ASSAY FOR THE LONG PCR OF THE Xba I POLYMORPHISM IN THE FACTOR VIII GENE
GAUCHER'S DISEASE: THE IMPACT OF ENZYME REPLACEMENT THERAPY
ACTIVATED PROTEIN C INHIBITS LIPOPOLYSACCHARIDE INDUCED INCREASE IN TUMOUR NECROSIS FACTOR-α AT PROTEIN AND MESSENGER-RNA LEVEL
A ROLE FOR CD36 IN THE MODULATION OF DENDRITIC CELL FUNCTION
PLATELET-MEDIATED CLUMPING OF P. FALCIPARUM INFECTED ERYTHROCYTES IS A COMMON ADHESIVE PHENOTYPE AND IS ASSOCIATED WITH SEVERE MALARIA
A MIS-SENSE MUTATION IN THE PLATELET GLYCOPROTEIN CD36 IS ASSOCIATED WITH PROTECTION FROM MALARIA
PROPHYLACTIC PLATELET TRANSFUSIONS FOR BONE MARROW FAILURE: RESULTS OF A SYSTEMATIC AUDIT.
ASSESSMENT OF THE ESR PLUS™-NOVEL TECHNOLOGY FOR THE MEASUREMENT OF ERYTHROCYTE SEDIMENTATION RATE (ESR), HAEMOGLOBIN (HB) AND HAEMATOCRIT (HCT)
A ROLE FOR DIGITAL IMAGING OF BLOOD AND BONE MARROW CELLS IN NATIONAL QUALITY CONTROL SCHEMES AND AS A TEACHING AID
Naja naja VENOM INDUCES NEUTROPHIL MOTILITY AND TRANSMIGRATION
EFFECTS OF CHEMOTHERAPY, RADIOTHERAPY AND CYTOKINES ON HAEMOPOIETIC PROGENITOR CELL PROLIFERATION.
DETECTION OF INTRA-ERYTHROCYTE MALARIAL PARASITES BY AN AUTOMATED HAEMATOLOGY ANALYSER-A CASE STUDY.
PATIENTS WITH RENAL AND RHEUMATOID DISEASE HAVE A DECREASED IMMATURE RETICULOCYTE FRACTION.
AUDIT OF EPISODES OF INVASIVE ASPERGILLOSIS IN BONE MARROW TRANSPLANT AND CHEMOTHERAPY PATIENTS OVER A TWO YEAR PERIOD.
NEW DIAGNOSTIC METHOD FOR IDENTIFICATION OF FUNGI CAUSING INVASIVE INFECTION IN HAEMATOLOGY PATIENTS
INVESTIGATION OF TREATMENT FAILURE IN INVASIVE ASPERGILLOSIS BY TESTING THE SUSCEPTIBILITY OF DEEP TISSUE ISOLATES.
CYTOGENETICS OF MULTIPLE MYELOMA. INTERPRETATION OF FISH RESULTS.
CHROMOSOMAL ABNORMALITIES IN SYSTEMIC AL AMYLOIDOSIS.
Reduced Vitamin-E Antioxidant Capacity correlates with non-transferrin bound iron in Sickle Cell patients as determined by Pholasin Chemiluminescence.
TELECLINICS: A YEAR OF EXPERIENCE
EARLY DIRECTED BRONCHOALVEOLAR LAVAGE IMPROVES THE MANAGEMENT OF PULMONARY INFILTRATES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY ON THE ICU - SEVERITY SCORING INDICES AS PREDICTORS OF SURVIVAL
BONE MINERAL DENSITY (BMD) IN HAEMATOLOGY PATIENTS TREATED WITH CORTICOSTEROIDS.
MAY-HEGGLIN ANOMALY - A DIFFERENT PERSPECTIVE USING BAYER ADVIA™120 PLATELET ANALYSIS.
SARCOIDOSIS: AN UNRECOGNISED REASON FOR EXACERBATION OF SICKLE CELL DISORDERS.
SURVIVAL IN β-THALASSAEMIA MAJOR: A SINGLE CENTRE STUDY.
STABILIZING SUGARS WITHIN INTRAVENOUS IMMUNOGLOBULIN (IVIg) PREPARATIONS EXHIBIT A CYTOTOXIC EFFECT TOWARDS THP-1 CELLS IN VITRO, AND NOT IVIg PER SE
TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE (TA-GvHD) AFTER THE TRANSFUSION OF LEUCOCYTE-DEPLETED (LD) RED CELLS
REINFUSION OF SALVAGED DRAIN BLOOD FOLLOWING TOTAL KNEE REPLACEMENT: AN AUDIT
INTO WHOM IS THE BLOOD SUPPLY GOING? A SINGLE CENTRE PILOT STUDY.
COMPARATIVE REGIONAL AUDIT OF THE USE OF RED CELL TRANSFUSION IN PATIENTS UNDERGOING PRIMARY HIP REPLACEMENT
COMPARATIVE REGIONAL AUDIT OF BLOOD TRANSFUSION PRACTICE
AUDIT AND REAUDIT OF THE APPROPRIATENESS OF THE USE OF FRESH FROZEN PLASMA (FFP)
FLUORESCENT LABELLED HYDROXYETHYL STARCH (FITCHES) CAN BE USED TO MEASURE PLASMA VOLUME IN THE CRITICALLY ILL.
FLUORESCENT LABELLED HYDROXYETHYL STARCH (FITCHES) MAY BE USED TO MEASURE PLASMA VOLUME IN THE INVESTIGATION OF A RAISED HAEMATOCRIT.
ELECTRONIC CROSS MATCH IN A DISTRICT GENERAL HOSPITAL
BLOOD AND BLOOD PRODUCTS TRANSFUSION RECORD - A COMBINED PRESCRIPTION SHEET, NURSING GUIDELINE AND PATIENT INFORMATION SHEET
AUDIT OF BLOOD USAGE IN A MAXILLOFACIAL SURGICAL UNIT, & ELIGIBILITY FOR AUTOLOGOUS PRE-DONATION
THE VALUE OF PLATELET ASSOCIATED IMMUNOGLOBULIN TESTING IN THE DIAGNOSIS OF ITP
PAROXYSMAL COLD HAEMOGLOBINURIA - A REPORT OF TWO LIFE THREATENING CASES.
THE NATIONAL BLOOD STOCKS PROJECT
A SURVEY OF INTRAOPERATIVE BLOOD LOSS AND CELL SALVAGE.
LONG-TERM FOLLOW-UP OF G-CSF RECEPTOR (G-CSFR) MUTATIONS IN SEVERE CONGENITAL NEUTROPENIA (SCN): IMPLICATIONS FOR LEUKAEMOGENESIS AND THERAPY
THE SPECTRUM AND SIGNIFICANCE OF SEQUENCE VARIATIONS IN THE FANCONI ANAEMIA GROUP C (FANCC) GENE IN CHILDREN WITH SPORADIC ACUTE MYELOID LEUKAEMIA.
HIERARCHICAL CYTOGENETIC CLASSIFICATION IS HIGHLY PREDICTIVE OF OUTCOME IN AML ARISING AT ALL AGES: AN ANALYSIS OF 4515 CASES ENTERED IN THE MRC AML 10, 11 & 12 TRIALS
AIRLINE TRAVEL; INCIDENCE AND PREVENTION OF VENOUS THROMBOSIS
TGF-β-MEDIATED MODULTION OF T CELL STAT3 AND STAT5 SIGNALLING IN MULTIPLE MYELOMA-EVIDENCE OF SYNERGY WITH IL-15.
RETROVIRAL MODIFICATION OF HAEMATOPOIETIC STEM CELLS IN VITRO PREVENTS ENGRAFTMENT ACROSS MHC BARRIERS
P53 DYSFUNCTION AS A CAUSE OF THE DRUG RESISTANCE AND SHORT SURVIVAL OF B-CLL PATIENTS WITH NON-HYPERMUTATED IgVH GENES.
A NOVEL GENE, NSD1, IS FUSED TO NUP98 IN THE t(5;11)(q35;p15.5) IN DE NOVO CHILDHOOD ACUTE MYELOID LEUKEMIA
A DUAL ROLE FOR p38 MAP KINASE IN PRIMARY HUMAN ERYTHROID PROGENITOR CELL DIFFERENTIATION AND APOPTOSIS
IN-VITRO EXPANSION OF CMV-SPECIFIC CD8+ T-CELLS USING AUTOLOGOUS DENDRITIC CELLS PULSED WITH CMV-PP65 PEPTIDES AND THEIR DETECTION AND QUANTITATION USING CMV-SPECIFIC HLA-TETRAMERS.
A SERINE/PROLINE RICH MOTIF IN THE GM-CSFRα2 ISOFORM INFLUENCES ERYTHROID AND MEGAKARYOCYTIC DIFFRENTIATION.
INVOLVEMENT OF THE RH COMPLEX AND CD47 IN HEREDITARY SPHEROCYTOSIS
CD38 EXPRESSION AND IgVH GENE MUTATION IN B-CLL.
CD38 EXPRESSION AND IGV GENE MUTATIONS ARE INDEPENDENT PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND CAN BE USED TO SELECT STAGE A PATIENTS FOR TREATMENT.
PK11195, A SMALL MOLEULE FOR APOPTOSIS SENSITISATION, AS A NOVEL THERAPY FOR CLL
PREDICTION OF OUTCOME IN NODAL DIFFUSE LARGE B CELL LYMPHOMA USING CELLULAR FACTORS IN COMBINATION WITH IPI
ISOLATION OF CYTOMEGALOVIRUS SPECIFIC CD8 T-CELLS FROM PERIPHERAL BLOOD USING HLA-PEPTIDE TETRAMERS AND MAGNETIC SELECTION.
ERYTHROPOIESIS AND IRON STATUS IN ASYMPTOMATIC SUBJECTS HOMOZYGOUS FOR HFE C282Y
A SOLUBLE FACTOR SECRETED BY PRIMARY AML CELLS BLOCKS T CELL CYCLE ENTRY AND PREVENTS T CELL APOPTOSIS
DNA MICROARRAY ANALYSIS OF bcr/abl MEDIATED GENE EXPRESSION.
FLOW CYTOMETRIC MONITORING IN MULTIPLE MYELOMA: THE RELATIONSHIP BETWEEN NORMAL AND NEOPLASTIC PLASMA CELLS PREDICTS OUTCOME POST-TRANSPLANT.
CAMPATH-1H WITH FLUDARABINE: A NOVEL, HIGHLY ACTIVE COMBINATION IN REFRACTORY CLL
AUTOCRINE bFGF INDUCED BY HAIRY-CELL INTERACTION WITH HYALURONAN (HA) IS RESPONSIBLE FOR THE DISTINCTIVE BONE MARROW FIBROSIS OF HAIRY-CELL LEUKAEMIA (HCL).
CLONAL B CELLS WITH A CLL PHENOTYPE ARE FREQUENTLY DETECTABLE IN NORMAL INDIVIDUALS.
ADULT ITP - A POPULATION BASED STUDY OF 343 CONSECUTIVE PATIENTS IN THE NORTHERN REGION.
MYCOPHENOLATE MOFETIL FOR TREATMENT OF SEVERE AUTOIMMUNE HAEMOLYTIC ANAEMIA AND IMMUNE THROMBOCYTOPENIA PURPURA.
THE SERIOUS HAZARDS OF TRANSFUSION (SHOT) SCHEME IS THE UK'S HAEMOVIGILANCE SYSTEM. THE FIRST THREE YEARS HAVE GIVEN US SOME VALUABLE INSIGHTS.
TWO NOVEL BETA-THALASSAEMIA MUTATIONS AND OTHER PREVALENT MUTATIONS IN INDIGENOUS SCOTTISH FAMILIES.
IDENTIFICATION AND CHARACTERISATION OF AN ERYTHROPOIETIN-INDUCED GENE, ERIC-1.
ENDOTHELIAL CELLS EXPRESS PRION PROTEIN
THE GENETIC BASIS OF PYRIMIDINE 5′ NUCLEOTIDASE DEFICIENCY
AUTOIMMUNE HAEMOLYTIC ANAEMIA - A HELPER T CELL DRIVEN DISEASE